| NEW YORK
NEW YORK Jan 13 The U.S. Supreme Court on
Friday agreed to hear a dispute over whether companies that make
copycat versions of biologic drugs must wait six months after
winning federal approval to begin selling them.
The justices will take up an appeal by Novartis AG
of a 2015 federal appeals court decision that prevented the
Swiss pharmaceutical company from selling its biosimilar version
of California-based Amgen Inc's $1-billion-a-year
Neupogen until six months after the Food and Drug Administration
approved it. The case could determine how quickly patients have
access to biosimilar medicines at potentially cheaper prices.
(Reporting by Andrew Chung; Editing by Will Dunham)